16:45 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Asana reports Phase Ib data for ASN002 in atopic dermatitis

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from a Phase Ib trial showing that atopic dermatitis candidate ASN002 was well tolerated. The most common adverse events reported were transient, mild headache and nausea. The double-blind,...
05:09 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from 36 patients with non-Hodgkin’s lymphoma (NHL) or advanced solid tumors in the dose-escalation Phase I portion of a Phase I/II trial showing that oral ASN002 was well...
00:38 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

ASN003: Ph I started

Asana began an open-label, U.S. Phase I trial to evaluate ASN003 in about 100 patients. A dose-escalation part will determine the dose for the expansion cohort in the second part, which will enroll patients with...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Asana Medical completes venture financing

Asana Medical Inc. , Miami Lakes, Fla.   Business: Autoimmune, Gastrointestinal   Date completed: 2016-05-10   Type: Venture financing   Raised: $1.2 million   Note: The financing comprises convertible promissory notes.  ...
00:02 , Oct 27, 2015 |  BC Extra  |  Company News

Management tracks

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF), which is developing therapeutics for acute kidney injury and traumatic brain injury, named Magnus Hansson CMO, effective Jan. 1, 2016. Hansson was consultant physician and associate professor at Lund University...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

University of Pittsburgh, Asana Medical deal

The university granted Asana exclusive, worldwide rights to multiple patents and patent applications covering methods and treatments for inflammatory bowel disease (IBD) without use of a colectomy. The patents include the use of extracellular matrix-derived...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Asana, Endo deal

Newco Asana acquired the early stage branded pharmaceutical discovery platform of Endo's Endo Pharmaceuticals Inc. subsidiary for an undisclosed upfront payment, plus milestones. The portfolio includes multiple preclinical compounds for cancer, pain and inflammation indications....